Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Pediatr Transplant ; 16(1): 83-91, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22122074

RESUMEN

Clinical end-points dictate large trial enrollments and exclude children with the rare intestine transplant procedure (ITx), who experience higher drug-related morbidity. We evaluate the novel rejection-risk parameter, allo-(antigen)-specific CD154 + TcMs (i) as surrogates for ACR using Prentice's criteria, (ii) for association with immunosuppression targets to determine Fleming's surrogate end-point designation, and (iii) as time-to-event end-point in a simulated comparison of alemtuzumab (NCT#01208337, n = 14) and rabbit anti-human thymocyte globulin (rATG, n = 16) among 30 children with ITx. CD154 + TcM were measured in MLR before, and at 1-60 and 61-200 days after ITx (NCT#01163578). CD154 + TcM correlate significantly with rejection severity (Spearman r = 0.685, p = 2.03E-5) and associate with biopsy-proven ITx rejection with sensitivity/specificity of 94%/84% [corrected] independent of immunosuppressant. Previously stated sensitivity of 90% is incorrect. [corrected]. The rejection-risk threshold of CD154 + TcM resolves rapidly in 200-day follow-up (46 ± 20 vs. 158 ± 59 days, p = 0.009, K-M) with alemtuzumab, which demonstrates lower 90-day ACR incidence (50% vs. 69%, p=NS, Fisher's exact), and is associated with accelerated prednisone minimization to ≤2.5 mg/day, compared with rATG (120 ± 28 vs. 180 ± 30 days, p = 0.027, K-M). As a surrogate end-point, time-to-rejection-risk resolution measured with CD154 + TcM portends 50% reduction in sample sizes in a simulated trial of alemtuzumab vs. rATG. Rejection-risk assessment with CD154 + TcM may enable informed immunosuppression minimization, and preliminary efficacy comparisons in pediatric ITx.


Asunto(s)
Ligando de CD40/biosíntesis , Memoria Inmunológica , Intestinos/trasplante , Linfocitos T/metabolismo , Trasplante/métodos , Adolescente , Suero Antilinfocítico/metabolismo , Biomarcadores/metabolismo , Niño , Preescolar , Rechazo de Injerto , Humanos , Inmunosupresores/uso terapéutico , Lactante , Pediatría/métodos , Riesgo , Sensibilidad y Especificidad , Trasplante Homólogo/métodos
2.
Crit Care Med ; 36(10): 2878-87, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18828196

RESUMEN

BACKGROUND: Thrombocytopenia-associated multiple organ failure (TAMOF) is a poorly understood syndrome in critically ill children. A disintegrin and metalloprotease with thrombospondin motifs (ADAMTS-13), formerly known as von Willebrand factor (VWF) cleaving protease, is decreased in adults with VWF-mediated thrombotic microangiopathy, and intensive plasma exchange (PEx) both replenishes ADAMTS-13 and improves outcome in these patients. OBJECTIVES: To determine whether: 1) critically ill children with TAMOF syndrome have decreased ADAMTS-13 activity, 2) ADAMTS-13 activity correlates with platelet counts and VWF antigen, 3) the autopsies from patients who died with reduced ADAMTS-13 activity have VWF-rich microthrombi, and 4) intensive PEx will restore ADAMTS-13 activity and facilitate organ failure resolution. DESIGN: First study: observational. Second study: randomized control trial. SETTING: Single center university pediatric intensive care unit. PATIENTS: First study: thirty-seven consecutive children (17 males and 20 females; ages ranging from 9 days to 23 years) identified with > or = 2 organs dysfunction were enrolled. Seventy-six percent of these children had thrombocytopenia (platelet counts < 100,000/mm3). Five additional critically ill children without MOF were also enrolled. In the second study, children with severe TAMOF (platelet counts < 100,000/mm3 and > 3 organ failure) were randomized to PEx or standard therapy. Primary physicians and parents agreed to enrollment in 10 of the 20 eligible patients with ages ranging from 1 year to 18 years. Five patients received PEx and 5 patients received standard therapy. RESULTS: First study: children with TAMOF (n = 28) had decreased ADAMTS-13 activity, but similar plasminogen activator inhibitor-1 activity and prothrombin time compared to children with MOF without thrombocytopenia (n = 9, p < 0.05). All non-survivors (n = 7) had TAMOF, reduced ADAMTS-13 activity, and VWF-rich microvascular thromboses at autopsy. In the second study, PEx (n = 5, median 12 days, 4-28 days) restored ADAMTS-13 activity and organ function, compared to standard therapy (n = 5, p < 0.05). CONCLUSIONS: Children with TAMOF syndrome can have VWF-mediated thrombotic microangiopathy. Similar to adult experience, PEx can replenish ADAMTS-13 activity and reverse organ failure.


Asunto(s)
Proteínas ADAM/sangre , Insuficiencia Multiorgánica/terapia , Intercambio Plasmático/métodos , Trombocitopenia/terapia , Proteínas ADAM/efectos de los fármacos , Proteína ADAMTS13 , Adolescente , Adulto , Factores de Edad , Análisis de Varianza , Biomarcadores/sangre , Niño , Preescolar , Enfermedad Crítica/mortalidad , Enfermedad Crítica/terapia , Femenino , Estudios de Seguimiento , Humanos , Lactante , Recién Nacido , Modelos Logísticos , Masculino , Insuficiencia Multiorgánica/sangre , Insuficiencia Multiorgánica/complicaciones , Insuficiencia Multiorgánica/mortalidad , Valores de Referencia , Medición de Riesgo , Estadísticas no Paramétricas , Tasa de Supervivencia , Trombocitopenia/sangre , Trombocitopenia/complicaciones , Trombocitopenia/mortalidad , Resultado del Tratamiento
3.
Pediatr Dev Pathol ; 6(2): 156-9, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12574911

RESUMEN

Three children, two with liver transplants and one with acquired human immunodeficiency virus (HIV) infection, presented with hepatitis accompanied by elevated gamma glutamyl transpeptidase. Biopsies revealed cholangiohepatitis caused by adenovirus infection. There was a progressive loss of interlobular bile ducts in two of the patients. In one patient, infection of the biliary tree was marked by a necrotizing cholangitis, with adenoviral inclusions noted in the biliary epithelium. In each patient, there was evidence of adenovirus gastrointestinal infection. This is the first report of adenoviral infection of the biliary tree in humans. It is hypothesized that adenovirus cholangiohepatitis occurs as a result of ascending infection from the gastrointestinal tract to the biliary tree.


Asunto(s)
Infecciones por Adenovirus Humanos/complicaciones , Colangitis/etiología , Hepatitis Viral Humana/etiología , Huésped Inmunocomprometido , Infecciones Oportunistas/complicaciones , Adenoviridae/aislamiento & purificación , Preescolar , Colangitis/patología , Colangitis/fisiopatología , Femenino , Infecciones por VIH/inmunología , Hepatitis Viral Humana/patología , Hepatitis Viral Humana/fisiopatología , Humanos , Lactante , Trasplante de Hígado/inmunología , Masculino , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA